Vertex builds in gene editing yet again, with $1.2bn Arbor dealVertex Pharma has ramped up its involvement in gene-editing medicines for the third time in a matter of Share XVertex builds in gene editing yet again, with $1.2bn Arbor dealhttps://pharmaphorum.com/news/vertex-builds-in-gene-editing-yet-again-with-1-2bn-arbor-deal/
Intellia, Regeneron ace first trial with ‘in vivo’ CRISPR drugThe first ever clinical data with a CRISPR/Cas9 drug used to edit the genomes of cells within the Share XIntellia, Regeneron ace first trial with ‘in vivo’ CRISPR drughttps://pharmaphorum.com/news/intellia-regeneron-ace-first-trial-with-in-vivo-crispr-drug/
Nobel winner Charpentier’s CRISPR Therapeutics gets $900m in reworked Vertex dealCRISPR Therapeutics is to receive a hefty $900m payment from Vertex after the companies amended a collaboration to Share XNobel winner Charpentier’s CRISPR Therapeutics gets $900m in reworked Vertex dealhttps://pharmaphorum.com/news/nobel-winner-charpentiers-crispr-therapeutics-gets-900m-in-reworked-vertex-deal/
Vertex eyes controllable genetic drugs with $1.3bn Obsidian allianceVertex Pharma has ramped up its involvement in gene-editing medicines for the second time in a week, paying Share XVertex eyes controllable genetic drugs with $1.3bn Obsidian alliancehttps://pharmaphorum.com/news/vertex-eyes-controllable-genetic-drugs-with-1-3bn-obsidian-alliance/
Casting aside CRISPR scissors and making a point with base editorsDr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at Share XCasting aside CRISPR scissors and making a point with base editorshttps://pharmaphorum.com/r-d/views-analysis-r-d/immune-cell-therapies-crispr-cas9-gene-editing/
Gene editing: beyond the hypeGenome editing is an exciting but still nascent field, and companies in the area face as many obstacles Share XGene editing: beyond the hypehttps://pharmaphorum.com/r-d/views-analysis-r-d/genome-editing-sangamo-beyond-the-hype/
ASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disordersA gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta Share XASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disordershttps://pharmaphorum.com/news/ash-crispr-vertex-ctx001-hits-the-mark-in-red-cell-disorders/
CRISPR pioneers Doudna and Charpentier claim Nobel chemistry prizeDrs Emmanuelle Charpentier and Jennifer Doudna have won this year’s Nobel Prize for chemistry in recognition of their Share XCRISPR pioneers Doudna and Charpentier claim Nobel chemistry prizehttps://pharmaphorum.com/news/crispr-pioneers-doudna-and-charpentier-claim-nobel-chemistry-prize/
Stem cell transplant eradicates HIV in second patientA second man with HIV has been cured of the infection after receiving a transplant of stem cells Share XStem cell transplant eradicates HIV in second patienthttps://pharmaphorum.com/news/stem-cell-transplant-eradicates-hiv-in-second-patient/
